You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Improving ALS Diagnosis using Needle I-EMG

    SBC: Haystack Diagnostics, Inc.            Topic: 103

    PROJECT SUMMARY Needle electromyographyEMGremains the standard approach for assessing neuromuscular diseaseWhile the technique has proven to be clinically valuable over the lastyearsit has important limitationsThese include its not being sensitive to alterations in muscle composition and structureits inability to assess the contractile apparatus of muscleand its subjective nature with an inter rat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants

    SBC: 149 Medical Inc.            Topic: 103

    PROJECT SUMMARY ABSTRACT Every year in the United States aboutof theinfants born extremely prematureandltweeks gestational age and andltg birth weightELGAdevelop intraventricular hemorrhageIVHIVH is associated with high risk for cerebral palsy and significant intellectual disabilitycausing lifelong implications for affected children and their families and considerable economic burdenIVH is caused ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: Lyst Therapeutics LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Flexible Access Port for Extra-Cardiac Beating Heart Repair

    SBC: Nido Surgical, Inc            Topic: NHLBI

    ABSTRACT The overall goal of this Phase I STTR project is to develop an epicardial endoscopic instrumentCardioPort ECfor safe and precise dissection and stabilization of the heart surface to enable epicardial ablation of ventricular arrhythmiasEffective treatment of ventricular tachycardiaa lifethreatening arrhythmiain patients with ischemic heart disease often requires both endocardial and epicar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A universal mechanobiology tool for drug discovery in lung diseases

    SBC: Mechanobiologix L.L.C.            Topic: NHLBI

    Abstract Despite significant effortsno cure exists for the major respiratory diseases such as asthmaemphysema and pulmonary fibrosis due to a lack of proper preclinical methodsDrug development is often carried out in cultured cellsWhile amenable to imaging and manipulationthis approach lacks the native tissue environment and neglects the effects of mechanical forces due to breathing which influenc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government